World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
44259
World Ranking
8810
National Ranking
4539

Overview

Andrew Siderowf is affiliated with the University of Pennsylvania in the United States. Their research focuses primarily on the field of medicine, with a specialization in neurology, physiology, psychiatry and mental health, cognitive neuroscience, and sensory systems. Their work addresses various neurological disorders with a strong emphasis on Parkinson's disease mechanisms and treatments. Other prominent topics in their research include Alzheimer's disease research and treatments, dementia and cognitive impairment research, botulinum toxin and related neurological disorders, autism spectrum disorder research, and olfactory and sensory function studies.

They have contributed to multiple research papers, including:

  • Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study (2023, The Lancet Neurology)
  • A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research (2024, The Lancet Neurology)
  • Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020, JAMA Neurology)
  • Trial of Cinpanemab in Early Parkinson's Disease (2022, New England Journal of Medicine)
  • Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease (2022, Science Translational Medicine)

Andrew Siderowf frequently collaborates with several researchers, including:

  • Kenneth Marek
  • Daniel Weintraub
  • Lana M. Chahine
  • Michael C. Brumm
  • Tanya Simuni

The scientist publishes often in these venues:

  • Neurology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Movement Disorders
  • Journal of Parkinson s Disease
  • npj Parkinson s Disease

Best Publications

  • Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

    Christopher G. Goetz;Barbara C. Tilley;Stephanie R. Shaftman;Glenn T. Stebbins

  • Projected number of people with parkinson disease in the most populous nations, 2005 through 2030

    E. R. Dorsey;R. Constantinescu;R. Constantinescu;J. P. Thompson;K. M. Biglan

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients

    Daniel Weintraub;Juergen Koester;Marc N. Potenza;Andrew D. Siderowf

  • Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

    S. Hoops;S. Nazem;A. D. Siderowf;J. E. Duda

  • Association of dopamine agonist use with impulse control disorders in Parkinson disease.

    Daniel Weintraub;Andrew D. Siderowf;Marc N. Potenza;Joseph Goveas

  • Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology

    D. Cella;J. S. Lai;C. J. Nowinski;D. Victorson

  • Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

    John L Robinson;Edward B Lee;Sharon X Xie;Lior Rennert

  • A controlled trial of rasagiline in early Parkinson disease: The tempo study

    Andrew Siderowf;Matthew Stern;Ira Shoulson;Karl Kieburtz

  • The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

    Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  • Validation of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease

    Daniel Weintraub;Staci Hoops;Judy A. Shea;Judy A. Shea;Kelly E. Lyons

  • Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.

    Hanae Nakashima-Yasuda;Kunihiro Uryu;John Robinson;Sharon X. Xie

  • Impulse control disorders in parkinson disease: A multicenter case–control study

    Valerie Voon;Mandy Sohr;Anthony E. Lang;Marc N. Potenza

  • Montreal Cognitive Assessment Performance in Patients with Parkinson’s Disease with “Normal” Global Cognition According to Mini-Mental State Examination Score

    Sarra Nazem;Andrew D. Siderowf;John E. Duda;Tom Ten Have

  • Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease

    Ju-Hee Kang;Ju-Hee Kang;David J. Irwin;Alice S. Chen-Plotkin;Andrew Siderowf

  • CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

    A. Siderowf;S.X. Xie;H. Hurtig;D. Weintraub

  • A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

    M Flint Beal;David Oakes;Ira Shoulson

  • Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients

    Atsushi Umemura;Jurg L. Jaggi;Howard I. Hurtig;Andrew D. Siderowf

  • Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale

    Daniel Weintraub;Eugenia Mamikonyan;Kimberly Papay;Judith A. Shea;Judith A. Shea

  • Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study

    B Ravina;M Putt;A Siderowf;J T Farrar

Frequent Co-Authors

Daniel Weintraub
Daniel Weintraub University of Pennsylvania
Matthew B. Stern
Matthew B. Stern University of Pennsylvania
John E. Duda
John E. Duda University of Pennsylvania
John Q. Trojanowski
John Q. Trojanowski University of Pennsylvania
Howard I. Hurtig
Howard I. Hurtig University of Pennsylvania
Sharon X. Xie
Sharon X. Xie University of Pennsylvania
Caroline M. Tanner
Caroline M. Tanner University of California, San Francisco
Danna Jennings
Danna Jennings Denali Therapeutics (United States)
Murray Grossman
Murray Grossman University of Pennsylvania
Mark A. Mintun
Mark A. Mintun University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean becoming a doctor. There are many alternative and in-demand healthcare roles that offer flexibility, strong job outlook, and rewarding career advancement possibilities. For example, those interested in administrative work may consider taking medical coding and billing classes online with financial aid, which can lead to vital roles in healthcare documentation and support.

Nursing remains one of the most popular and accessible entry points to healthcare. You may wonder, do all nursing schools require the teas? The answer is no—some programs do not require the TEAS or HESI exams, making the admissions process less daunting for prospective students.

For individuals seeking leadership roles, pursuing an accelerated healthcare administration degree online can help open doors to management and executive positions in hospitals, clinics, and other medical organizations.

Nurses aiming to advance their practice may also look into asn to nurse practitioner programs, which allow registered nurses to bridge their credentials and qualify for higher-responsibility roles in clinical care.

Best Scientists Citing Andrew Siderowf

Trending Scientists